Silk Road Medical: Q3 Earnings Insights

Shares of Silk Road Medical SILK were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 19.23% over the past year to ($0.31), which missed the estimate of ($0.28).

Revenue of $20,067,000 up by 17.86% year over year, which beat the estimate of $19,590,000.

Guidance

Silk Road Medical hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 10, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/5vjzk4nx

Price Action

Company's 52-week high was at $75.80

Company's 52-week low was at $20.84

Price action over last quarter: Up 39.22%

Company Profile

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. Its approach for the treatment of carotid artery disease is called as transcarotid artery revascularization, or TCAR. The TCAR relies on two concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain.